

AMERICAN MEDICAL ASSOCIATION ORGANIZED MEDICAL STAFF SECTION

Resolution: 5
(A-26)

Introduced by: Matthew Gold, MD

Subject: Medical Staff Oversight of Hospital Augmented Intelligence

Referred to: OMSS Reference Committee
(, MD, Chair)

1 Whereas, the core mission of the American Medical Association (AMA) is to promote the art and
2 science of medicine and the betterment of public health; the organization focuses on
3 empowering physicians to improve patient care, advancing medical science, and enhancing the
4 professional lives of doctors; and
5

6 Whereas, the evolution and insertion of augmented/artificial intelligence tools is accelerating
7 and already having a direct impact on the provision of health care with “cause for both optimism
8 and caution, as no one can predict with certainty how life will be changed a decade from now
9 due to AI’s vast potential;”¹ and
10

11 Whereas, the American Hospital Association has communicated to the U.S. Department of
12 Health and Human Services (HHS), including the following: “However, it is important that the
13 ongoing expansion and adoption of AI in health care be handled carefully, and that
14 policymakers balance the need for flexibility to foster innovation with the right policy guardrails
15 to ensure patient safety and improve patient experience...We recommend policies that ensure
16 clinicians are included in the decision loop for algorithms that may impact access to care or care
17 delivery, such as prior authorizations, consistent privacy and security standards for third-party
18 vendors, and post-development standards for health care AI developers to ensure ongoing
19 integrity of tools;”² and
20

21 Whereas, the AMA has extensive policy related to augmented/artificial intelligence; and
22

23 Whereas, in particular, reference is made to the role physicians should play in quality control,
24 such that: “...our AMA will advocate that...national medical specialty societies and state medical
25 associations 1. Identify areas of medical practice where AI systems would advance the
26 quadruple aim, 2. Leverage existing expertise to ensure clinical validation and clinical
27 assessment of clinical applications of AI systems by medical experts, 3. Outline new
28 professional roles and capacities required to aid and guide health care AI systems, 4. Develop
29 practical guidelines for clinical applications of AI systems;”³ and
30

31 Whereas, the AMA has provided general guidance that “health care AI requires a risk-based
32 approach where the level of security, validation, and oversight should be proportionate to the
33 overall potential of disparate harm and consequences the AI system might introduce” and
34 “Generative AI should (a) only be used where appropriate policies are in place within the
35 practice or other health care organization to govern its use and help mitigate associated risks;”⁴
36 and
37

38 Whereas, medical departmental and specialty meetings are an established process by which
39 hospital care and patient safety are assessed; therefore be it

1
2
3
4
5
6
7
8

RESOLVED, that our American Medical Association recommends medical staffs of hospitals and other medical treatment establishments schedule and hold regular, timely physician-led meetings (e.g. weekly, biweekly or monthly) to review management outcomes of all patients whose care involved augmented/artificial intelligence recommendations in the interval between meetings, and also review proposed treatment as well as any delayed consequences of prior care that may have arisen (Directive to Take Action).

Fiscal Note: (Assigned by HOD)

Received: 4/24/2026

REFERENCES

1. "Tapping Into AI's Potential for Supporting Great Patient Care," Apr 03, 2026 - 08:18 AM by Rick Pollack, President and CEO, American Hospital Association;
<https://www.aha.org/news/perspective/2026-04-03-tapping-ais-potential-supporting-great-patient-care>
2. *Ibid*
3. AMA Policy H-480.939, "Augmented Intelligence in Health Care"
<https://policysearch.ama-assn.org/policyfinder/detail/Augmented%20Intelligence%20in%20Health%20Care%20H-480.940?uri=%2FAMADoc%2FHOD.xml-H-480.940.xml>
4. AMA Policy H-480.931, "Assessing the Intersection Between AI and Health Care"
<https://policysearch.ama-assn.org/policyfinder/detail/Assessing%20the%20Intersection%20Between%20AI%20and%20Health%20Care%20H-480.931?uri=%2FAMADoc%2FHOD.xml-H-480.931.xml>

RELEVANT AMA POLICY

Augmented Intelligence in Health Care H-480.940

As a leader in American medicine, our American Medical Association has a unique opportunity to ensure that the evolution of augmented intelligence (AI) in medicine benefits patients, physicians, and the health care community.

To that end our AMA will seek to:

1. Leverage its ongoing engagement in digital health and other priority areas for improving patient outcomes and physicians' professional satisfaction to help set priorities for health care AI.
2. Identify opportunities to integrate the perspective of practicing physicians into the development, design, validation, and implementation of health care AI.
3. Promote development of thoughtfully designed, high-quality, clinically validated health care AI that:
 - a. is designed and evaluated in keeping with best practices in user-centered design, particularly for physicians and other members of the health care team;
 - b. is transparent;
 - c. conforms to leading standards for reproducibility;
 - d. identifies and takes steps to address bias and avoids introducing or exacerbating health care disparities including when testing or deploying new AI tools on vulnerable populations; and
 - e. safeguards patients' and other individuals' privacy interests and preserves the security and integrity of personal information.
4. Encourage education for patients, physicians, medical students, other health care professionals, and health administrators to promote greater understanding of the promise and limitations of health care AI.
5. Explore the legal implications of health care AI, such as issues of liability or intellectual property, and advocate for appropriate professional and governmental oversight for safe, effective, and equitable use of and access to health care AI.

Citation: BOT Rep. 41, A-18; Reaffirmed: CMS Rep. 01, A-24; Reaffirmed; CSAPH Rep. 08, A-25

Augmented Intelligence in Health Care H-480.939

Our American Medical Association supports the use and payment of augmented intelligence (AI) systems that advance the quadruple aim. AI systems should enhance the patient experience of care and outcomes, improve population health, reduce overall costs for the health care system while increasing value, and support the professional satisfaction of physicians and the health care team. To that end our AMA will advocate that:

1. Oversight and regulation of health care AI systems must be based on risk of harm and benefit accounting for a host of factors, including but not limited to: intended and reasonably expected use(s); evidence of safety, efficacy, and equity including

- addressing bias; AI system methods; level of automation; transparency; and, conditions of deployment.
2. Payment and coverage for all health care AI systems must be conditioned on complying with all appropriate federal and state laws and regulations, including, but not limited to those governing patient safety, efficacy, equity, truthful claims, privacy, and security as well as state medical practice and licensure laws.
 3. Payment and coverage for health care AI systems intended for clinical care must be conditioned on
 - a. clinical validation.
 - b. alignment with clinical decision-making that is familiar to physicians.
 - c. high-quality clinical evidence.
 4. Payment and coverage for health care AI systems must
 - a. be informed by real world workflow and human-centered design principles.
 - b. enable physicians to prepare for and transition to new care delivery models.
 - c. support effective communication and engagement between patients, physicians, and the health care team.
 - d. seamlessly integrate clinical, administrative, and population health management functions into workflow.
 - e. seek end-user feedback to support iterative product improvement.
 5. Payment and coverage policies must advance affordability and access to AI systems that are designed for small physician practices and patients and not limited to large practices and institutions. Government-conferred exclusivities and intellectual property laws are meant to foster innovation, but constitute interventions into the free market, and therefore, should be appropriately balanced with the need for competition, access, and affordability.
 6. Physicians should not be penalized if they do not use AI systems while regulatory oversight, standards, clinical validation, clinical usefulness, and standards of care are in flux. Furthermore, our AMA opposes:
 - a. Policies by payers, hospitals, health systems, or governmental entities that mandate use of health care AI systems as a condition of licensure, participation, payment, or coverage.
 - b. The imposition of costs associated with acquisition, implementation, and maintenance of healthcare AI systems on physicians without sufficient payment.
 7. Liability and incentives should be aligned so that the individual(s) or entity(ies) best positioned to know the AI system risks and best positioned to avert or mitigate harm do so through design, development, validation, and implementation. Our AMA will further advocate:
 - a. Where a mandated use of AI systems prevents mitigation of risk and harm, the individual or entity issuing the mandate must be assigned all applicable liability.
 - b. Developers of autonomous AI systems with clinical applications (screening, diagnosis, treatment) are in the best position to manage issues of liability arising directly from system failure or misdiagnosis and must accept this liability with measures such as maintaining appropriate medical liability insurance and in their agreements with users.
 - c. Health care AI systems that are subject to non-disclosure agreements concerning flaws, malfunctions, or patient harm (referred to as gag clauses) must not be covered or paid and the party initiating or enforcing the gag clause assumes liability for any harm.
 8. Our AMA, national medical specialty societies, and state medical associations:
 - a. Identify areas of medical practice where AI systems would advance the quadruple aim.

- b. Leverage existing expertise to ensure clinical validation and clinical assessment of clinical applications of AI systems by medical experts.
 - c. Outline new professional roles and capacities required to aid and guide health care AI systems.
 - d. Develop practice guidelines for clinical applications of AI systems.
9. There should be federal and state interagency collaboration with participation of the physician community and other stakeholders in order to advance the broader infrastructural capabilities and requirements necessary for AI solutions in health care to be sufficiently inclusive to benefit all patients, physicians, and other health care stakeholders. (New HOD Policy)
10. AI is designed to enhance human intelligence and the patient-physician relationship rather than replace it.

Citation: BOT Rep. 21, A-19; Reaffirmed: A-22; Reaffirmed: CSAPH Rep. 08, A-25; Reaffirmed: Res. 226, A-25

Assessing the Intersection Between AI and Health Care H-480.931

Augmented Intelligence Development, Deployment, and Use in Health Care

1. General Governance
 - a. Health care AI must be designed, developed, and deployed in a manner which is ethical, equitable, responsible, accurate, transparent, and evidence-based.
 - b. Use of AI in health care delivery requires clear national governance policies to regulate its adoption and utilization, ensuring patient safety, and mitigating inequities. Development of national governance policies should include interdepartmental and interagency collaboration.
 - c. Compliance with national governance policies is necessary to develop AI in an ethical and responsible manner to ensure patient safety, quality, and continued access to care. Voluntary agreements or voluntary compliance is not sufficient.
 - d. AI systems should be developed and evaluated with a specific focus on mitigating bias and promoting health equity, ensuring that the deployment of these technologies does not exacerbate existing disparities in health care access, treatment, or outcomes.
 - e. Health care AI requires a risk-based approach where the level of scrutiny, validation, and oversight should be proportionate to the overall potential of disparate harm and consequences the AI system might introduce [See also Augmented Intelligence in Health Care H-480.939 at (1)]
 - f. AI risk management should minimize potential negative impacts of health care AI systems while providing opportunities to maximize positive impacts.
 - g. Clinical decisions influenced by AI must be made with specified qualified human intervention points during the decision-making process. A qualified human is defined as a licensed physician with the necessary qualifications and training to independently provide the same medical service without the aid of AI. As the potential for patient harm increases, the point in time when a physician should utilize their clinical judgment to interpret or act on an AI recommendation should occur earlier in the care plan. With few exceptions, there generally should

- be a qualified human in the loop when it comes to medical decision making capable of intervening or overriding the output of an AI model.
- h. Health care practices and institutions should not utilize AI systems or technologies that introduce overall or disparate risk that is beyond their capabilities to mitigate. Implementation and utilization of AI should avoid exacerbating clinician burden and should be designed and deployed in harmony with the clinical workflow and, in institutional settings, consistent with AMA Policy H-225.940 - Augmented Intelligence and Organized Medical Staff.
 - i. Medical specialty societies, clinical experts, and informaticists are best positioned and should identify the most appropriate uses of AI-enabled technologies relevant to their clinical expertise and set the standards for AI use in their specific domain. [See Augmented Intelligence in Health Care H-480.940 at (2)]
2. When to Disclose: Transparency in Use of Augmented Intelligence-Enabled Systems and Technologies That Impact Medical Decision Making at the Point of Care
 - a. Decisions regarding transparency and disclosure of the use of AI should be based upon a risk- and impact-based approach that considers the unique circumstance of AI and its use case. The need for transparency and disclosure is greater where the performance of an AI-enabled technology has a greater risk of causing harm to a patient.
 - i. AI disclosure should align and meet ethical standards or norms.
 - ii. Transparency requirements should be designed to meet the needs of the end users. Documentation and disclosure should enhance patient and physician knowledge without increasing administrative burden.
 - iii. When AI is used in a manner which impacts access to care or impacts medical decision making at the point of care, that use of AI should be disclosed and documented to both physicians and/or patients in a culturally and linguistically appropriate manner. The opportunity for a patient or their caregiver to request additional review from a licensed clinician should be made available upon request.
 - iv. When AI is used in a manner which directly impacts patient care, access to care, medical decision making, or the medical record, that use of AI should be documented in the medical record.
 - b. AI tools or systems cannot augment, create, or otherwise generate records, communications, or other content on behalf of a physician without that physician's consent and final review.
 - c. When AI or other algorithmic-based systems or programs are utilized in ways that impact patient access to care, such as by payors to make claims determinations or set coverage limitations, use of those systems or programs must be disclosed to impacted parties.
 - d. The use of AI-enabled technologies by hospitals, health systems, physician practices, or other entities, where patients engage directly with AI, should be clearly disclosed to patients at the beginning of the encounter or interaction with the AI-enabled technology. Where patient-facing content is generated by AI, the use of AI in generating that content should be disclosed or otherwise noted within the content.
 3. What to Disclose: Required Disclosures by Health Care Augmented Intelligence-Enabled Systems and Technologies
 - a. When AI-enabled systems and technologies are utilized in health care, the following information should be disclosed by the AI developer

to allow the purchaser and/or user (physician) to appropriately evaluate the system or technology prior to purchase or utilization:

- i. Regulatory approval status.
 - ii. Applicable consensus standards and clinical guidelines utilized in design, development, deployment, and continued use of the technology.
 - iii. Clear description of problem formulation and intended use accompanied by clear and detailed instructions for use.
 - iv. Intended population and intended practice setting.
 - v. Clear description of any limitations or risks for use, including possible disparate impact.
 - vi. Description of how impacted populations were engaged during the AI lifecycle.
 - vii. Detailed information regarding data used to train the model:
 1. Data provenance.
 2. Data size and completeness.
 3. Data timeframes.
 4. Data diversity.
 5. Data labeling accuracy.
 - viii. Validation Data/Information and evidence of:
 1. Clinical expert validation in intended population and practice setting and intended clinical outcomes.
 2. Constraint to evidence-based outcomes and mitigation of “hallucination”/“confabulation” or other output error.
 3. Algorithmic validation.
 4. External validation processes for ongoing evaluation of the model performance, e.g., accounting for AI model drift and degradation.
 5. Comprehensiveness of data and steps taken to mitigate biased outcomes.
 6. Other relevant performance characteristics, including but not limited to performance characteristics at peer institutions/similar practice settings.
 7. Post-market surveillance activities aimed at ensuring continued safety, performance, and equity.
 - ix. Data Use Policy:
 1. Privacy.
 2. Security.
 3. Special considerations for protected populations or groups put at increased risk.
 - x. Information regarding maintenance of the algorithm, including any use of active patient data for ongoing training.
 - xi. Disclosures regarding the composition of design and development team, including diversity and conflicts of interest, and points of physician involvement and review.
- b. Purchasers and/or users (physicians) should carefully consider whether or not to engage with AI-enabled health care technologies if this information is not disclosed by the developer. As the risk of AI being incorrect increases risks to patients (such as with clinical applications of AI that impact medical decision making), disclosure of this information becomes increasingly important. [See also Augmented Intelligence in Health Care H-480.939]
4. Generative Augmented Intelligence
- a. Generative AI should: (a) only be used where appropriate policies are in place within the practice or other health care organization to govern its use and help

- mitigate associated risks; and (b) follow applicable state and federal laws and regulations (e.g., HIPAA-compliant Business Associate Agreement).
- b. Appropriate governance policies should be developed by health care organizations and account for and mitigate risks of:
 - i. Incorrect or falsified responses; lack of ability to readily verify the accuracy of responses or the sources used to generate the response.
 - ii. Training data set limitations that could result in responses that are out of date or otherwise incomplete or inaccurate for all patients or specific populations.
 - iii. Lack of regulatory or clinical oversight to ensure performance of the tool.
 - iv. Bias, discrimination, promotion of stereotypes, and disparate impacts on access or outcomes.
 - v. Data privacy.
 - vi. Cybersecurity.
 - vii. Physician liability associated with the use of generative AI tools.
 - c. Health care organizations should work with their AI and other health information technology (health IT) system developers to implement rigorous data validation and verification protocols to ensure that only accurate, comprehensive, and bias managed datasets inform generative AI models, thereby safeguarding equitable patient care and medical outcomes. [See Augmented Intelligence in Health Care H-480.940 at (3)(d)]
 - d. Use of generative AI should incorporate physician and staff education about the appropriate use, risks, and benefits of engaging with generative AI. Additionally, physicians and healthcare organizations should engage with generative AI tools only when adequate information regarding the product is provided to physicians and other users by the developers of those tools.
 - e. Clinicians should be aware of the risks of patients engaging with generative AI products that produce inaccurate or harmful medical information (g., patients asking chatbots about symptoms) and should be prepared to counsel patients on the limitations of AI-driven medical advice.
 - f. Data and prompts contributed by users should primarily be used by developers to improve the user experience and AI tool quality and not simply increase the AI tool's market value or revenue generating potential.
5. Physician Liability for Use of Augmented Intelligence-Enabled Technologies
- a. Current AMA policy states that liability and incentives should be aligned so that the individual(s) or entity(ies) best positioned to know the AI system risks and best positioned to avert or mitigate harm do so through design, development, validation, and implementation. [See Augmented Intelligence in Health Care H-480.939]
 - i. Where a mandated use of AI systems prevents mitigation of risk and harm, the individual or entity issuing the mandate must be assigned all applicable liability.
 - ii. Developers of autonomous AI systems with clinical applications (screening, diagnosis, treatment) are in the best position to manage issues of liability arising directly from system failure or misdiagnosis and must accept this liability with measures such as maintaining appropriate medical liability insurance and in their agreements with users.
 - iii. Health care AI systems that are subject to non-disclosure agreements concerning flaws, malfunctions, or patient harm (referred to as gag

- clauses) must not be covered or paid and the party initiating or enforcing the gag clause assumes liability for any harm.
- b. When physicians do not know or have reason to know that there are concerns about the quality and safety of an AI-enabled technology, they should not be held liable for the performance of the technology in question.
 - c. Liability protections for physicians using AI-enabled technologies should align with both current and future AMA medical liability reform policies.
6. Data Privacy and Augmented Intelligence
- a. Entity Responsibility:
 - i. Entities, e.g., AI developers, should make information available about the intended use of generative AI in health care and identify the purpose of its use. Individuals should know how their data will be used or reused, and the potential risks and benefits.
 - ii. Individuals should have the right to opt-out, update, or request deletion of their data from generative AI tools. These rights should encompass AI training data and disclosure to other users of the tool.
 - iii. Generative AI tools should not reverse engineer, reconstruct, or reidentify an individual's originally identifiable data or use identifiable data for nonpermitted uses, e.g., when data are permitted to conduct quality and safety evaluations. Preventive measures should include both legal frameworks and data model protections, e.g., secure enclaves, federated learning, and differential privacy.
 - b. User Education:
 - i. Users should be provided with training specifically on generative AI. Education should address:
 1. Legal, ethical, and equity considerations.
 2. Risks such as data breaches and re-identification.
 3. Potential pitfalls of inputting sensitive and personal data.
 4. The importance of transparency with patients regarding the use of generative AI and their data.

[See H-480.940, Augmented Intelligence in Health Care, at (4) and (5)]

7. Augmented Intelligence Cybersecurity
 - a. AI systems must have strong protections against input manipulation and malicious attacks.
 - b. Entities developing or deploying health care AI should regularly monitor for anomalies or performance deviations, comparing AI outputs against known and normal behavior.
 - c. Independent of an entity's legal responsibility to notify a health care provider or organization of a data breach, that entity should also act diligently in identifying and notifying the individuals themselves of breaches that impact their personal information.
 - d. Users should be provided education on AI cybersecurity fundamentals, including specific cybersecurity risks that AI systems can face, evolving tactics of AI cyber attackers, and the user's role in mitigating threats and reporting suspicious AI behavior or outputs.
8. Mitigating Misinformation in AI-Enabled Technologies
 - a. AI developers should ensure transparency and accountability by disclosing how their models are trained and the sources of their training data. Clear disclosures are necessary to build trust in the accuracy and reliability of the information produced by AI systems.

- b. Algorithms should be developed to detect and flag potentially false and misleading content before it is widely disseminated.
 - c. Developers of AI should have mechanisms in place to allow for reporting of mis- and disinformation generated or propagated by AI-enabled systems.
 - d. Developers of AI systems should be guided by policies that emphasize rigorous validation and accountability for the content their tools generate, and, consistent with AMA Policy H-480.939(7), are in the best position to manage issues of liability arising directly from system failure or misdiagnosis and must accept this liability with measures such as maintaining appropriate medical liability insurance and in their agreements with users.
 - e. Academic publications and journals should establish clear guidelines to regulate the use of AI in manuscript submissions. These guidelines should include requiring the disclosure that AI was used in research methods and data collection, requiring the exclusion of AI systems as authors, and should outline the responsibility of the authors to validate the veracity of any referenced content generated by AI.
 - f. Education programs are needed to enhance digital literacy, helping individuals critically assess the information they encounter online, particularly in the medical field where mis- and disinformation can have severe consequences.
9. Payor Use of Augmented Intelligence and Automated Decision-Making Systems
- a. Use of automated decision-making systems that determine coverage limits, make claim determinations, and engage in benefit design should be publicly reported, based on easily accessible evidence-based clinical guidelines (as opposed to proprietary payor criteria), and disclosed to both patients and their physician in a way that is easy to understand.
 - b. Payors should only use automated decision-making systems to improve or enhance efficiencies in coverage and payment automation, facilitate administrative simplification, and reduce workflow burdens. Automated decision-making systems should never create or exacerbate overall or disparate access barriers to needed benefits by increasing denials, coverage limitations, or limiting benefit offerings. Use of automated decision-making systems should not replace the individualized assessment of a patient's specific medical and social circumstances and payors' use of such systems should allow for flexibility to override automated decisions. Payors should always make determinations based on particular patient care needs and not base decisions on algorithms developed on "similar" or "like" patients.
 - c. Payors using automated decision-making systems should disclose information about any algorithm training and reference data, including where data were sourced and attributes about individuals contained within the training data set (e.g., age, race, gender). Payors should provide clear evidence that their systems do not discriminate, increase inequities, and that protections are in place to mitigate bias.
 - d. Payors using automated decision-making systems should identify and cite peer-reviewed studies assessing the system's accuracy measured against the outcomes of patients and the validity of the system's predictions.
 - e. Any automated decision-making system recommendation that indicates limitations or denials of care, at both the initial review and appeal levels, should be automatically referred for review to a physician (a) possessing a current and valid non-restricted license to practice medicine in the state in which the proposed services would be provided if authorized and (b) be of the same specialty as the physician who typically manages the medical condition or disease or provides the health care service involved in the request

prior to issuance of any final determination. Prior to issuing an adverse determination, the treating physician must have the opportunity to discuss the medical necessity of the care directly with the physician who will be responsible for determining if the care is authorized.

- f. Individuals impacted by a payor's automated decision-making system, including patients and their physicians, must have access to all relevant information (including the coverage criteria, results that led to the coverage determination, and clinical guidelines used).
- g. Payors using automated decision-making systems should be required to engage in regular system audits to ensure use of the system is not increasing overall or disparate claims denials or coverage limitations, or otherwise decreasing access to care. Payors using automated decision-making systems should make statistics regarding systems' approval, denial, and appeal rates available on their website (or another publicly available website) in a readily accessible format with patient population demographics to report and contextualize equity implications of automated decisions. Insurance regulators should consider requiring reporting of payor use of automated decision-making systems so that they can be monitored for negative and disparate impacts on access to care. Payor use of automated decision-making systems must conform to all relevant state and federal laws.

Citation: BOT Rep. 01, I-24; Reaffirmed: CSAPH Rep. 08, A-25; Reaffirmed in lieu of the first resolve: Res. 226, A-25